Orexo’s nasal adrenaline rescue medication OX640 enters clinical development
· OX640 has the potential to provide important benefits to patients and healthcare systems ensuring the correct adrenaline dose is both reliably and conveniently available - for the emergency treatment of allergic reactions · If approved, the product will target a global growing market, today amounting to USD 2 billion · Development and commercial partnerships are considered Uppsala, Sweden – July 5, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study (OX640-001) for OX640, an adrenaline rescue